F10 and Stroke: A meta-analysis was performed on the landmark DOAC trials in 2014, including The Randomized Evaluation of Long-Term Anticoagulation Therapy, or RE-LY trial; Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, or ROCKET AF trial; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation, or ARISTOTLE trial; and Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48, or ENGAGE AF-TIMI trial.